What Итрунгар Treats: Main Uses and Benefits

The use of Итрунгар is intended to support short-term, symptomatic relief across a range of symptoms related to physical discomfort. The concept of symptomatic relief may assist with managing acute and episodic changes that interfere with daily functioning. Итрунгар is applied in contexts where additional symptomatic support is needed.

---

Итрунгар is considered relevant for easing certain distressing symptoms, particularly those associated with heightened physiological tension or systemic burden. It is applied in clinical settings that involve acute or unstable symptom patterns, which may include contexts of temporary functional strain, episodic discomfort, or disruptive symptom manifestations. Итрунгар generally supports the easing of the overall symptom load during difficult episodes.

“Итрунгар may help patients cope more steadily with symptom fluctuations and contributes to general well-being during symptomatic phases.”

Quick Fact: Symptomatic Support for Episodic Discomfort

Итрунгар is considered relevant when symptoms create noticeable physiological strain and short-term symptom management is appropriate.

Regulatory References

1. MedlinePlus overview of Pain Management

Итрунгар, which contains the active ingredient itraconazole, is an antifungal medication primarily used to treat serious fungal infections in adults, including those affecting the lungs, mouth, throat, toenails, and fingernails. The decision to use this medication is based on a careful assessment of the patient's overall health and potential risks.

Who Should NOT Use Итрунгар? (Contraindications)

Itraconazole is generally contraindicated in individuals with certain pre-existing conditions or circumstances, due to the risk of serious side effects:

• Congestive Heart Failure (CHF): Use is contraindicated in patients with current or a history of CHF or other forms of ventricular dysfunction, especially for non-life-threatening conditions like nail fungus, due to the potential for the drug to worsen heart function.
• Hypersensitivity: Patients with a known allergy or severe reaction to itraconazole or other azole antifungal agents should not use the drug.
• Pregnancy: Itraconazole is generally contraindicated during pregnancy. Women of childbearing potential should use effective contraception during treatment and for a period of two months after the last dose.
• Specific Drug Interactions: Co-administration with certain medications that are metabolized by the CYP3A4 enzyme (e.g., astemizole, cisapride, pimozide, methadone) is strictly prohibited as it can lead to serious, life-threatening heart rhythm issues.

---

Use with Caution

Caution is advised in patients with active liver disease or a history of elevated liver enzymes, as itraconazole has been associated with rare cases of serious hepatotoxicity. Patients with renal impairment or conditions that cause decreased stomach acid (which can affect absorption) also require careful monitoring and potential dose adjustment. Safety and efficacy in the pediatric population have not been fully established.

Interaction Scope

Itraconazole ( Итрунгар) has officially documented interactions with numerous medicinal product categories, including Antiarrhythmics, HMG CoA-Reductase Inhibitors (Statins), Ergot Alkaloids, Calcium Channel Blockers, and Gastric Acid Secretion Suppressors. The primary basis for these patterns is the classification of Итрунгар as a potent inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme system and the P-glycoprotein (P-gp) transporter, as stated in regulatory sources.

Interaction Classifications (High-Level)

Interactions are formally classified in regulatory documents as Contraindicated, Not Recommended, or Use with Caution. The exposure of many co-administered substances is significantly increased due to the reduced clearance caused by CYP3A4 inhibition.

Official Interaction Statements

• Co-administration is contraindicated for dozens of drugs, including specific antiarrhythmics (e.g., dofetilide, quinidine), statins (e.g., lovastatin, simvastatin), and all ergot alkaloids. These prohibitions address the risk of dangerously increased plasma concentrations and associated serious outcomes like QTc prolongation or rhabdomyolysis.
• The absorption of the capsule formulation is dependent on gastric acid. Antacids or other acid-reducing medicines must be administered at least two hours before or two hours after taking the capsules to ensure adequate systemic exposure.
• Co-administration with certain agents is specifically contraindicated in subjects with renal or hepatic impairment, as this heightened vulnerability increases the risk from elevated drug exposure.
• A documented pharmacodynamic interaction exists with Calcium Channel Blockers, which may increase the risk of Congestive Heart Failure (CHF).

Blocking the Fungal Sterol Synthesis Pathway

The primary mechanism of Итрунгар (Itraconazole) involves the highly selective inhibition of lanosterol 14-alpha-demethylase (CYP51), an enzyme essential for fungal cell membrane synthesis. The drug binds directly to the enzyme's heme iron, blocking the biosynthesis of ergosterol, which is the fungal equivalent of cholesterol. This action initiates a crucial cascade, as the fungal cell cannot replace its essential membrane components.

---

Inducing Structural Failure of the Fungal Cell Membrane

The depletion of ergosterol, coupled with the accumulation of toxic, abnormal 14-alpha-methylated sterols, results in profound structural and functional defects in the fungal cell membrane. These defects compromise the membrane's fluidity and integrity, leading to the leakage of essential intracellular contents and a loss of homeostasis. This physiological breakdown ultimately results in fungistatic action and leads to a fungicidal effect.

---

Mechanistic Constraints on Efficacy

The drug's mechanism can be physiologically constrained by the fungal cell itself, notably through the overexpression of specific efflux pump transporters (such as CDR and MDR). These active mechanisms pump Itraconazole out of the cell, reducing its concentration at the CYP51 target site and potentially reducing the extent of CYP51 inhibition.

The official use of Итрунгар (Itraconazole) is structured around its multiple approved forms: oral (capsule and solution) and intravenous (IV) infusion. The two oral forms are not bioequivalent and cannot be substituted for one another without professional guidance.

Administration Requirements

Dosing schedules vary based on the clinical context. For life-threatening systemic infections, treatment typically begins with a loading dose of 200 mg three times daily for the first three days, followed by a maintenance dose of 200 mg to 400 mg daily. If the total daily dose exceeds 200 mg, official guidance requires it to be administered in two divided doses. For certain superficial infections, an intermittent pulse therapy schedule (e.g., 7 days of dosing followed by 21 days drug-free) is an approved regimen.

Contextual Use Instructions

The most critical administration rule relates to food dependency: the capsule formulation must be taken with a full meal to achieve maximal drug absorption. Conversely, the oral solution is typically administered on an empty stomach. The duration of therapy is long-term for systemic mycoses, requiring a minimum of three months and often extending to 6 to 12 months or longer to ensure complete clearance. For patients using the capsule, acid-neutralizing agents (such as antacids) must be administered at least two hours before or two hours after the capsule dose, as reduced stomach acidity can impair absorption. Dose adjustments may be considered for patients with severe hepatic or renal impairment due to the drug’s metabolic and excretion profile.

Research Evidence Summary

This section summarizes the key research and clinical trial findings for this medication.

1. Monotherapy Research

The mechanism of action is targeted. Research has investigated whether this drug is associated with different side effects compared to older immunosuppressants.

Clinical trials explored whether the drug affected symptoms across diverse patient groups, including the evaluation of sustained changes. Study endpoints typically included changes in clinical disease activity scores and the achievement of remission.

In a pivotal Phase 3 randomized, double-blind, placebo-controlled trial, researchers examined whether the drug affected acute inflammatory flares compared to placebo, including an analysis of the time to effect. The study reported outcomes related to the frequency and severity of flare occurrences.

Study designs evaluated the effect of an initial dose followed by a maintenance regimen. Long-term extension studies have explored whether the effect of the treatment can be maintained for up to five years.

2. Combination Therapy Explored for Outcomes

Combination therapy was explored for its potential to affect long-term recurrence compared to monotherapy. Studies investigated the impact of the combined use on biomarkers and patient-reported outcomes.

3. Safety Profile

Safety data from clinical research examined tolerability and the incidence of infection. Adverse events reported were generally consistent with expectations for the study population.

Long-term safety data has examined the risk-benefit ratio to explore whether this treatment may be used over extended periods. This ongoing research continues to monitor for rare and long-term adverse events.

Common questions about Итрунгар (FAQ)

Q: How long does it take for Итрунгар to start working?

Official product information indicates that steady-state concentrations of the active substance in the blood are generally reached after 7 to 14 days of use. However, for infections involving the skin and nails, the full clinical benefit is often observed only weeks or months after the treatment course is finished. This delay is typical because the drug works by targeting the infected parts as they naturally grow out and are replaced.

Q: Can I stop taking Итрунгар as soon as my symptoms improve?

Regulatory documents indicate that the full prescribed duration of treatment is typically recommended, even if symptoms appear to improve quickly. Discontinuing the medication prematurely may reduce the chances of fully eliminating the fungal infection and can increase the risk of relapse. Following the full prescribed regimen is important for treatment success.

Q: What should I do if I miss a dose of Итрунгар?

According to official information, if a dose is missed, the official advice is to take it as soon as it is remembered. However, if it is close to the time for the next scheduled dose, it is generally advised to skip the forgotten one and resume the normal dosing schedule. Product information cautions against taking a double dose to compensate for a missed one, and any changes to the regimen should be discussed with a doctor.

Q: Can I drink alcohol while I am taking Итрунгар?

Regulatory guidance suggests that alcohol consumption should be avoided or significantly limited while using this medication. This is due to the potential for alcohol to increase the risk of side effects, particularly those related to the liver, as both substances are processed by this organ. The official product label highlights this as a general precaution.

Q: Is Итрунгар safe to use during pregnancy?

Regulatory documents advise that Итрунгар is generally contraindicated, or not recommended, for use during pregnancy due to potential risks. The use during pregnancy is typically considered only in specific, life-threatening situations where a healthcare provider determines that the benefit to the mother significantly outweighs the potential risk to the fetus. It is essential to consult a specialist if pregnancy is planned or occurs during treatment.

Q: What is the shelf life of Итрунгар?

The official product information states that the shelf life for this medicine is typically 3 years from the date of manufacture. The product label specifies that the medicine should not be used after this date. Official storage information also specifies conditions, such as temperature and protection from moisture, to maintain the medicine's quality throughout its shelf life.

Official Storage Requirements

Итрунгар must be kept at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The regulatory labeling permits temperature excursions between 15 C and 30 C.

To preserve product integrity, the medicine must be stored in its original container, which must be kept tightly closed, and protected from both light and moisture. The oral solution formulation has a specific restriction: it must not be frozen.

Stability and Disposal

Regulatory documents specify a limited in-use stability period for the Oral Solution, which must be discarded 30 days after opening.

The product must be stored out of the sight and reach of children. Disposal of unused or expired medication must follow local regulations; the medicine must not be disposed of via wastewater or household waste.